Company / Shareholders' Equity
Haemonetics Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$820.8M
FY2025
5-year range
$731.7M / $960.0M
FY2021-FY2025
Trend
-14.5%
vs FY2024
Sector context
#94 of 166
Health Care
What the data says
At $821M, Haemonetics's shareholders' equity ranks #94 of 166 in the Health Care sector. Shareholders' Equity has fluctuated over the past 10 years, ranging from $587M in FY2020 to $960M in FY2024.
Based on SEC 10-K filings.
$821M in FY2025 with a 5-year CAGR of +6.9%.
Remained stable around $821M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +3.1%
- 5-Year CAGR
- +6.9%
- 10-Year CAGR
- -
Sector benchmark
#94 of 166 in Health CareTop 57% of 166This company $820.8M Sector average $5.3B
▼
-84.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +6.9%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 14.5% year-over-year.
- Ranks #94 out of 166 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $820.8M | -14.5% |
| FY2024 | $960.0M | +17.4% |
| FY2023 | $818.0M | +9.2% |
| FY2022 | $749.4M | +2.4% |
| FY2021 | $731.7M | +24.6% |
| FY2020 | $587.1M | -12.1% |
| FY2019 | $667.9M | -11.2% |
| FY2018 | $752.4M | +1.7% |
| FY2017 | $739.6M | +2.5% |
| FY2016 | $721.6M | -12.7% |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026